Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib.
Bornhäuser
Martin
M
Pursche
Stefan
S
Bonin
Malte
M
Freiberg-Richter
Jens
J
Jenke
Andreas
A
Illmer
Thomas
T
Ehninger
Gerhard
G
Schleyer
Eberhard
E
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy*; D010879:Piperazines / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014018:Tissue Distribution
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases